Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516802 | 0.92 | MAPK1 (0.51) | MAPTHSD11B1PDK2CYP2D6AVPR1A | |
| SCHEMBL13606665 | 0.91 | PDK2 (0.50) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4512269 | 0.90 | PDK2 (0.48) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4518852 | 0.90 | HSD11B1 (0.49) | HSD11B1PDK2CYP2D6AVPR1ANPY5R | |
| SCHEMBL4516336 | 0.89 | HSD11B1 (0.50) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4507956 | 0.89 | MAPT (0.44) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4526266 | 0.89 | PDK2 (0.48) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4526269 | 0.89 | PDK2 (0.48) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4508489 | 0.89 | HSD11B1 (0.43) | MAPTSMN1; SMN2HSD11B1PDK2CYP2D6 | |
| SCHEMBL4519969 | 0.88 | HSD11B1 (0.47) | HSD11B1PDK2CYP2D6AVPR1ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | claimed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | HSD11B1, HSD11B2, HSD17B1 | MAPT 3956/4885SMN1; SMN2 3944/4885HSD11B1 1/4885 |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | HSD11B1, HSD11B2, HSD17B1 | MAPT 3956/4885SMN1; SMN2 3944/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.